Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NBTY Aiming To Double Rexall Earnings; Closes Deal

This article was originally published in The Tan Sheet

Executive Summary

NBTY plans to double newly acquired Rexall Sundown's earnings before interest, taxes, depreciation and amortization (EBITDA) to $78 mil. in the next nine months

You may also be interested in...



NBTY CFO Kamil Anticipates Rebound In Vitamin Market Around The Corner

NBTY will have to cycle through another quarter in order to have a clearer picture of its Rexall and retail businesses with regard to year-over-year comparisons, CFO Harvey Kamil said

NBTY CFO Kamil Anticipates Rebound In Vitamin Market Around The Corner

NBTY will have to cycle through another quarter in order to have a clearer picture of its Rexall and retail businesses with regard to year-over-year comparisons, CFO Harvey Kamil said

NBTY CFO Kamil Anticipates Rebound In Vitamin Market Around The Corner

NBTY will have to cycle through another quarter in order to have a clearer picture of its Rexall and retail businesses with regard to year-over-year comparisons, CFO Harvey Kamil said

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS095743

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel